Skip to main content

Search

Reset all filters
731 Result(s)
Sort by

Our goal of transforming the treatment of neuroendocrine carcinomas

Our goal of transforming the treatment of neuroendocrine carcinomas

Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).
Catherine Alonzo

Catherine Alonzo

Catherine Alonzo, Patient Safety Physician, Metabolism, tells us about the importance of drug surveillance.
Careers: Winning with people

Careers: Winning with people

Our employees are the foundation of our innovative strength. We continue to put people first in everything we do and support our employees in the key moments of their careers.
Partnering Vanderbilt WCNDD

Partnering Vanderbilt WCNDD

Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
university-of-medical-excellence-harvard

university-of-medical-excellence-harvard

A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
Quality

Quality

At Boehringer Ingelheim, Quality is deeply embedded into the lifecycle of the product: from Research and development to the delivery to our patients.
CHMP_opinion_nintedanib_ILD_PF

CHMP_opinion_nintedanib_ILD_PF

Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Our Partners Bioharmony

Our Partners Bioharmony

Chandra Ghose, Founder and CEO of Bioharmony Therapeutics, talks about the urgent need for developing new antimicrobials and the benefits of partnering with Boehringer Ingelheim.
Improving Access to Healthcare

Improving Access to Healthcare

According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.
Boehringer Ingelheim acquires Nerio Therapeutics

Boehringer Ingelheim acquires Nerio Therapeutics

Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
Our Vision

Our Vision

At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.